Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

PET/CT Imaging Clinical Trial

Official title: Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to assess new low radiation dose techniques for clinical PET/CT scans through intra-individual comparison between a clinical, standard dose scan and a low-dose scan, completed within one week of each other.

Clinical Trial Description

Positron Emission Tomography/Computed Tomography (PET/CT) imaging using 18F-FDG is an important, commonly used cancer, neuroscience and cardio-vascular imaging methodology to detect disease and to monitor therapeutic interventions. While considerable technological progress of PET/CT systems has occurred over the last decade, we have not re-evaluated the ability to potentially reduce the radiation burden of the used PET imaging pharmaceutical (FDG).

This early phase trial intends to accomplish the following:

• to validate that the radiation dose burden from the PET imaging pharmaceutical (FDG) can be reduced by more than 50% from the current standard of clinical care (SOC) level without affecting the diagnostic ability;

• to confirm that a low dose approach will be feasible for response assessment;

• to validate that the difference in FDG uptake between imaging 60 min +/- 10 min post injection and 75 min +/- 10 min post injection is independent/equivalent of the injected FDG dose

• to validate a simulation methodology to streamline future dose finding studies for PET imaging pharmaceuticals. ;

Related Conditions & MeSH terms

• PET/CT Imaging

• NCT number: NCT03519659
• Study type: Interventional
• Source: University of Cincinnati
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 21, 2015
• Completion date: December 31, 2024